Persistence of Candida albicans candidemia in non-neutropenic surgical patients: Management of a representative patient in the absence of second-line treatment guidelines

Journal of Chemotherapy

Volumn 19, Issue 3, 2007, Pages 335-338

  Pacini, D ^a   Cerana, M ^a   Beltrame, A ^a   Di Biagio, A ^a   De Maria, Andrea ^b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Antifungal treatment; Candida albicans; Candidemia; Sepsis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; MEROPENEM; METRONIDAZOLE; VANCOMYCIN;

ADULT; ANAMNESIS; ARTICLE; CANDIDA ALBICANS; CANDIDEMIA; CASE REPORT; CLINICAL FEATURE; DEBRIDEMENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION RISK; INTRAVASCULAR CATHETER; LOADING DRUG DOSE; NEUTROPENIA; PATHOGENESIS; PATIENT CARE; PERITONEUM LAVAGE; PERITONITIS; RECOMMENDED DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 34447505894     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.3.335     Document Type: Article

References (18)

1. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002; 40(9):3489-92.
2. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991; 91(3B):86S-89S.
3. Hadley S, Lee WW, Ruthazer R, Nasraway SA Jr. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Crit Care Med. 2002; 30(8): 1808-14.
4. Chen TC, Chen YH, Tsai JJ, et al. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan. J Microbiol Immunol Infect. 2005; 38(3):200-10.
5. Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect. 2005; 11(11):908-13.
6. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988; 148(12):2642-5.
7. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331(20):1325-30.
8. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997; 16(5):337-45.
9. Mora-Duarte J, Berts R, Rotstein C, et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347(25):2020-9.
10. Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004; 38(2):161-89.
11. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005; 41(3):e27-8.
12. Nolla-Salas J, Sitges-Serra A, Leon C, de la Torre MV, Sancho H. Candida endophthalmitis in non-neutropenic critically ill patients. Eur J Clin Microbiol Infect Dis. 1996; 15(6):503-6.
13. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006; 42(2):244-51.
14. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005; 366(9495): 1435-42.
15. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection. 2000; 28(4):223-6.
16. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001; 40(5-6):511-20.
17. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48:693-715
18. Meletiadis J, Petraitis V, Petraitiene R, et al. Triazolepolyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006; 194(7): 1008-18.